Compare NNDM & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNDM | TRDA |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 386.8M |
| IPO Year | N/A | 2021 |
| Metric | NNDM | TRDA |
|---|---|---|
| Price | $1.80 | $10.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.8M | 265.1K |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,663,000.00 | $61,520,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.75 | N/A |
| 52 Week Low | $1.31 | $4.93 |
| 52 Week High | $2.74 | $21.79 |
| Indicator | NNDM | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.24 | 70.75 |
| Support Level | $1.43 | $9.40 |
| Resistance Level | $1.65 | $10.75 |
| Average True Range (ATR) | 0.08 | 0.60 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 88.10 | 78.61 |
Nano Dimension Ltd provide industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research and academia, along with government organizations.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.